Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.59 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.59 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.59 |
| ▸ | JAK1 | P23458 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735325 | 0.88 | CYP1A2 (0.51) | TAS1R3TAS1R1TAS1R2JAK1RAB9A | |
| SCHEMBL733727 | 0.88 | JAK1 (0.61) | JAK1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL733959 | 0.82 | JAK1 (0.56) | TAS1R3TAS1R1TAS1R2JAK1RAB9A | |
| SCHEMBL733065 | 0.80 | JAK1 (0.53) | JAK1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL735276 | 0.79 | HDAC1 (0.55) | JAK1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL14991989 | 0.78 | JAK1 (0.75) | TAS1R3TAS1R1TAS1R2JAK1MEN1 | |
| SCHEMBL16583412 | 0.78 | RORC (0.57) | TAS1R3TAS1R1TAS1R2RAB9AMEN1 | |
| SCHEMBL9348863 | 0.78 | KMT2A (0.59) | TAS1R3TAS1R1TAS1R2RAB9AMEN1 | |
| SCHEMBL16583293 | 0.78 | JAK1 (0.69) | TAS1R3TAS1R1TAS1R2JAK1RAB9A | |
| SCHEMBL355407 | 0.77 | JAK1 (0.63) | TAS1R3TAS1R1TAS1R2JAK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695349-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3029041-B1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20200061062-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2020-02-27 | — | — | US | disclosed |
| US-10398695-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3046563-B1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AS PI3-KINASE INHIBITORS | CALITOR SCIENCES LLC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20180360832-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2018-12-20 | — | — | US | disclosed |
| US-10010550-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2018-07-03 | — | — | US | disclosed |
| CN-104513235-B | Substituted amino-metadiazine compound and its application method and purposes | 广东东阳光药业有限公司 | 2017-12-05 | — | — | CN | disclosed |
| US-20170340633-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-9670194-B2 | Substituted aminopyrimidine compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-6800620-B2 | CONTACTING LEUKOCYTES, OSTEOCLASTS WITH AN ENZYME INHIBITORS, A 9H-PURIN-3H-QUINAZOLIN-4-ONE DERIVATIVES, TREATING BONE-RESORPTION DISORDER, ANTIPROLIFERATIVE AGENTS TREATING LEUKEMIA CELLS | ICOS | 2004-10-05 | — | — | US | disclosed |
| EP-1438052-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL−INOSITOL 3−KINASE DELTA | ICOS CORPORATION (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6667300-B2 | Purinyl substituted quinazoline-4-one derivatives | ICOS CORPORATION | 2003-12-23 | — | — | US | disclosed |
| US-20030195211-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION | 2003-10-16 | — | — | US | disclosed |
| CN-1440408-A | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORP (US) | 2003-09-03 | — | — | CN | disclosed |
| WO-2003035075-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2003-05-01 | — | — | WO | disclosed |
| US-6518277-B1 | Disrupting leukocyte function | ICOS CORPORATION | 2003-02-11 | — | — | US | disclosed |
| EP-1278748-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | ICOS CORPORATION, A DELAWARE CORPORATION | 2002-10-31 | — | — | US | disclosed |
| WO-2001081346-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340633-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | TAS1R3 3827/4885TAS1R1 3900/4885TAS1R2 4164/4885 |
| US-20180360832-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | TAS1R3 3827/4885TAS1R1 3900/4885TAS1R2 4164/4885 |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | PIK3CD, PIK3CA, PIK3CG | TAS1R3 3806/4885TAS1R1 4159/4885TAS1R2 4345/4885 |
| US-20200061062-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | TAS1R3 3827/4885TAS1R1 3900/4885TAS1R2 4164/4885 |
| US-20030195211-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | TAS1R3 4301/4885TAS1R1 4435/4885TAS1R2 4566/4885 |
| US-10695349-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | TAS1R3 3827/4885TAS1R1 3900/4885TAS1R2 4164/4885 |
| US-10010550-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | TAS1R3 3827/4885TAS1R1 3900/4885TAS1R2 4164/4885 |
| US-10398695-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | TAS1R3 3827/4885TAS1R1 3900/4885TAS1R2 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.